Trilaciclib (Cosela) — CPB 0988 | AETNA Coverage Update

Aetna modified CPB 0988 for trilaciclib (Cosela), effective September 26, 2025. Here's what billing teams need to do before that date.

Aetna, a CVS Health company, updated its coverage policy for trilaciclib (Cosela) under CPB 0988 Aetna system. This update applies to commercial medical plans and requires precertification for HCPCS code J1448 (injection, trilaciclib, 1mg) billed alongside CPT 96365 for IV infusion. If your practice treats small cell lung cancer patients with myelosuppressive chemotherapy, this change lands directly in your revenue cycle.

Quick-Reference Table

Aetna Trilaciclib Coverage Criteria and Medical Necessity Requirements 2025

The Aetna trilaciclib coverage policy under CPB 0988 covers J1448 when specific medical necessity criteria are met. Precertification is required for all Aetna participating providers and members in applicable plan designs.

To request precertification, call Aetna at (866) 752-7021 or fax (888) 267-3277. If you need a Statement of Medical Necessity (SMN) form, find it through Aetna's Specialty Pharmacy Precertification portal. Don't wait until the day of infusion to start this process.

The primary diagnosis codes that support medical necessity for trilaciclib are small cell lung cancer diagnoses across the C34.x code family. Aetna maps 94 ICD-10-CM codes to this policy — all under the C34 category for malignant neoplasm of bronchus and lung. Use the most specific C34 subcategory that matches your patient's confirmed diagnosis. As a general coding best practice, unspecified codes carry higher denial risk than anatomically specific ones — though CPB 0988 does not state this as a precertification requirement.

This coverage policy applies to commercial plans only. If your patient is on Medicare, Aetna directs you to separate Medicare Part B criteria. Don't assume your commercial billing guidelines transfer to your Medicare population for this drug. Two different rule sets, same drug — a common source of claim denial.

One thing this policy update doesn't spell out in detail: the exact clinical criteria Aetna uses to approve or deny a precertification request. The CPB references medical necessity broadly, but the specific conditions — such as whether trilaciclib is limited to first-line treatment or extends to subsequent lines — aren't visible in the posted billing guidelines. If your prior authorization request comes back denied or pended, ask Aetna for the specific criterion that wasn't met. You have the right to that information before you appeal.

Coverage Indications at a Glance

Aetna Trilaciclib Billing Guidelines and Action Items 2025

These are the steps your billing team needs to take before the September 26, 2025 effective date.

CPT, HCPCS, and ICD-10 Codes for Trilaciclib Under CPB 0988

Covered HCPCS and CPT Codes (When Selection Criteria Are Met)

ICD-10-CM Diagnosis Codes

All 94 codes fall under the C34 category. The description below reflects the exact language used in CPB 0988 for every C34.x code listed in this policy. The ICD-10-CM tabular list contains additional anatomical specificity within these subcategories — use that as a coding reference to select the most precise code for your patient's documented diagnosis.

Note: The policy lists 94 total ICD-10-CM codes. The source data provided 80 codes explicitly. All fall within the C34.x range for small cell lung cancer. Pull the full list from CPB 0988 on Aetna's site to confirm all applicable subcategories for your patient population.

The Real Issue With This Policy Update

The precertification requirement is the heart of this change. Trilaciclib billing without a prior authorization number in hand is a guaranteed write-off on a drug that costs thousands of dollars per dose. The financial exposure here is high.

The policy is also silent on what happens if precertification is denied — there's no appeal pathway or step therapy requirement described in the publicly posted criteria. That silence matters. If your precert gets denied, you'll need to go back to Aetna and ask for the specific clinical rationale before you can build an appeal. Don't assume a denial is final.

If you're billing J1448 in a high-volume oncology or infusion center setting and you're not already tracking Aetna commercial prior auth approval rates for this drug, start now. If your approval rate drops after September 26, 2025, you need to know within days. Talk to your compliance officer if you're unsure how this policy applies to your specific plan mix or patient population.